Full Text
... and fibrosis (8). Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. A broad spectrum of histological manifestations including macrovesicular steatosis, liver cirrhosis, fibrosis, portal hypertension, and hepatocellular carcinoma are observed in NAFLD. The exosom ...
... and fibrosis (8). Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. A broad spectrum of histological manifestations including macrovesicular steatosis, liver cirrhosis, fibrosis, portal hypertension, and hepatocellular carcinoma are observed in NAFLD. The exosom ...
The innate immune system in cystic fibrosis lung disease Perspective
... the innate defense system include alveolar macrophages, neutrophils, and epithelial cells.These cells provide not only effector functions against pathogens but also initiate or coordinate the host response to infection (Fig. 1). Secretions of the airways contain proteins and peptides that directly k ...
... the innate defense system include alveolar macrophages, neutrophils, and epithelial cells.These cells provide not only effector functions against pathogens but also initiate or coordinate the host response to infection (Fig. 1). Secretions of the airways contain proteins and peptides that directly k ...
Clinical Synopsis A 32year old female presented with a four year
... The pathologic mechanism of vitiligo is not clearly known. Complex factors involving cellular and humoral immunity, toxic metabolites and genetic factors partly contribute to its pathogenesis. Ciuet al5 demonstrated that antibodies to melanocytes were present in both vitiligo and melanoma patients w ...
... The pathologic mechanism of vitiligo is not clearly known. Complex factors involving cellular and humoral immunity, toxic metabolites and genetic factors partly contribute to its pathogenesis. Ciuet al5 demonstrated that antibodies to melanocytes were present in both vitiligo and melanoma patients w ...
Human Anatomy, First Edition McKinley&O`Loughlin
... vaccine may provide lifelong immunity, or periodic booster shots may be needed ...
... vaccine may provide lifelong immunity, or periodic booster shots may be needed ...
0018
... Th1 response protected mice against L. major infection.11 Handman et al mentioned that prophylactic DNA vaccination shifted the T cellderived cytokine environment with an increase in the INF-gamma-producing Th1 type cells.12 Cabrera et al showed that by using live Mycobacterium bovis BCG and heated ...
... Th1 response protected mice against L. major infection.11 Handman et al mentioned that prophylactic DNA vaccination shifted the T cellderived cytokine environment with an increase in the INF-gamma-producing Th1 type cells.12 Cabrera et al showed that by using live Mycobacterium bovis BCG and heated ...
Human T-lymphotropic virus type 1 (HTLV
... in HAM/TSP patients3). We and other researchers have reported that the maturation and function of HTLV-1specific CTLs are impaired in HAM/TSP patients, although in vitro studies have shown that these CTLs exert cytolytic activity against HTLV-1expressing target cells6,7). Therefore, we hypothesize t ...
... in HAM/TSP patients3). We and other researchers have reported that the maturation and function of HTLV-1specific CTLs are impaired in HAM/TSP patients, although in vitro studies have shown that these CTLs exert cytolytic activity against HTLV-1expressing target cells6,7). Therefore, we hypothesize t ...
Evaluation of the Cell-mediated Immune
... cell-mediated response appeared at 7 to 8 days after virus induced sarcoma tissue culture cell lines as target cells. inoculation, reached a peak at 13 to 14 days, and then Cellular cytotoxicity was detected as early as 3 days after declined rapidly (23, 26). In contrast, with visual MCA the virus i ...
... cell-mediated response appeared at 7 to 8 days after virus induced sarcoma tissue culture cell lines as target cells. inoculation, reached a peak at 13 to 14 days, and then Cellular cytotoxicity was detected as early as 3 days after declined rapidly (23, 26). In contrast, with visual MCA the virus i ...
Nature Medicine Essay - The Lasker Foundation
... explore the events that take place after dendritic cells and T cells begin to interact, when dendritic cells start to express cytokines and use other molecules such as CD40 and CD70 to generate strong adaptive resistance54,62. Dendritic cells comprise several different forms or subsets, each having ...
... explore the events that take place after dendritic cells and T cells begin to interact, when dendritic cells start to express cytokines and use other molecules such as CD40 and CD70 to generate strong adaptive resistance54,62. Dendritic cells comprise several different forms or subsets, each having ...
Immunology Overview
... indicate a bacterial infection. PMNs have azurophilic granules (lysosomes and defensins) and specific granules (complement receptors, adhesion molecules). These sentinel cells phagocytose professionally. Macrophages live for weeks/months, are active in chronic inflammation, present antigen, release ...
... indicate a bacterial infection. PMNs have azurophilic granules (lysosomes and defensins) and specific granules (complement receptors, adhesion molecules). These sentinel cells phagocytose professionally. Macrophages live for weeks/months, are active in chronic inflammation, present antigen, release ...
Why Stem Cells - Stem Cell Banking
... • While most blood stem cells reside in the bone marrow, a small number are present in the bloodstream. These multipotent PBSCs, can be used just like bone marrow stem cells to treat leukemia, other cancers and various blood disorders • PBSCs are easier to collect than bone marrow stem cells • PBSCs ...
... • While most blood stem cells reside in the bone marrow, a small number are present in the bloodstream. These multipotent PBSCs, can be used just like bone marrow stem cells to treat leukemia, other cancers and various blood disorders • PBSCs are easier to collect than bone marrow stem cells • PBSCs ...
Lymphocyte Interactions and Immune Responses
... properties： （1）are large polymeric molecules with multiple, repeating, antigenic determinants （2）have some poorly defined mitogenic properties （polyclonal activators）: at high concentrations they are able to activate B-cell clones to poliferate and to produce antibody。 ...
... properties： （1）are large polymeric molecules with multiple, repeating, antigenic determinants （2）have some poorly defined mitogenic properties （polyclonal activators）: at high concentrations they are able to activate B-cell clones to poliferate and to produce antibody。 ...
miRNA-124 in Immune System and Immune Disorders
... T lymphocytes are the main executors of the adaptive immune responses. miR-124 is reported to exert potent anti-glioma therapeutic effects via a T cell-mediated antitumor immune response. Glioma cancer stem cells (gCSCs) produce immunosuppressive roles in the T-cell proliferation, and miR-124 could ...
... T lymphocytes are the main executors of the adaptive immune responses. miR-124 is reported to exert potent anti-glioma therapeutic effects via a T cell-mediated antitumor immune response. Glioma cancer stem cells (gCSCs) produce immunosuppressive roles in the T-cell proliferation, and miR-124 could ...
Introduction to the Immune System
... The Complement System Infection results in activation of complement proteins via a series of proteolytic reactions that yield biologically active fragments. These coupled proteolytic reactions result in an amplification cascade, in which limited stimulation of proximal complement components results ...
... The Complement System Infection results in activation of complement proteins via a series of proteolytic reactions that yield biologically active fragments. These coupled proteolytic reactions result in an amplification cascade, in which limited stimulation of proximal complement components results ...
ELF-MF induce cell activation via the alternative pathway in immune
... This is the first study to show that LF EMF exposure is able to enhance NET formation ex vivo. An increased NET formation of ~25% could be measured at four hours after stimulation with PMA. Cellular activation was needed, since LF EMF exposure alone was not able to promote NET formation. The pathway ...
... This is the first study to show that LF EMF exposure is able to enhance NET formation ex vivo. An increased NET formation of ~25% could be measured at four hours after stimulation with PMA. Cellular activation was needed, since LF EMF exposure alone was not able to promote NET formation. The pathway ...
The primary lymphoid organs include the thymus and bone marrow
... constantly exposed to a wide variety of potentially harmful microorganisms and therefore require their own system of antigen capture and presentation to lymphocytes. For example, Peyer’s patches, which are mucosa-associated lymphoid tissues of the small intestine, sample passing antigens and expose ...
... constantly exposed to a wide variety of potentially harmful microorganisms and therefore require their own system of antigen capture and presentation to lymphocytes. For example, Peyer’s patches, which are mucosa-associated lymphoid tissues of the small intestine, sample passing antigens and expose ...
T-Cell Research - BD Biosciences
... T cells. This brochure discusses and demonstrates how the following platforms can be used to study T-cell differentiation: Cell Surface Markers to identify cells from heterogenous samples Intracellular Cytokine Staining (ICS) to measure cytokines within individual cells BD Phosflow™ technology to me ...
... T cells. This brochure discusses and demonstrates how the following platforms can be used to study T-cell differentiation: Cell Surface Markers to identify cells from heterogenous samples Intracellular Cytokine Staining (ICS) to measure cytokines within individual cells BD Phosflow™ technology to me ...
Options for Patients with Advanced Stage Low Grade Follicular
... The other issue is several different chemotherapy regimes were used making the results a little difficult to tease out including one group who received both COPP and interferon. The other potential problem some specialists may have is that the research was conducted in Mexico. The results I feel spe ...
... The other issue is several different chemotherapy regimes were used making the results a little difficult to tease out including one group who received both COPP and interferon. The other potential problem some specialists may have is that the research was conducted in Mexico. The results I feel spe ...
... cells. At least a subpopulation of T-lymphocytes expressed all three receptors, but only Fas expression was observed on alveolar macrophages. 4-1BB is known to be expressed by activated (but not resting) T-lymphocytes. The detection of 4-1BB mRNA in activated B-cells, cytokine-treated monocytes and ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.